Evomela® (melphalan) – Indication withdrawal

- On August 9, 2021, the FDA approved the voluntary removal of Acrotech Biopharma's Evomela (melphalan) indication for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

- Evomela remains approved for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.

- Evomela carries a boxed warning for severe bone marrow suppression, hypersensitivity, and leukemogenicity.